• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Weight Loss Improves Atrial Fibrillation, Cardiometabolic Profile


Results of the LEGACY study show long-term weight loss decreases AF burden and supports sustained sinus rhythm. A short slide show summarizes the 2015 ACC late-breaking abstract.

The slides above summarize results of the Long-Term Effect of Goal Directed Weight Management on an Atrial Fibrillation Cohort (LEGACY) study. Researchers were interested in the dose-response effect of weight loss on the burden of atrial fibrillation (AF) as well as the impact of sustained vs fluctuating weight loss on AF symptoms. The participant group that had at least a 10% weight loss at 1 year (after a physician-led intervention) had more reductions in severe symptoms than groups that shed fewer pounds. They were also 6 times more likely to achieve arrhythmia-free survival.The results of the study were presented at the 2015 American College of Cardiology Scientific Sessions, Late Breaking Clinical Trials, in San Diego, March 14-16.


Pathak RK, Middeldorp ME, Meredith M, et al. Long-Term Effect of Goal Directed Weight Management in an Atrial Fibrillation Cohort: A Long-term Follow-Up StudY (LEGACY Study). J Am Coll Cardiol. 2015. doi:10.1016/j.jacc.2015.03.002.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
© 2024 MJH Life Sciences

All rights reserved.